Infliximab biosimilar - Nichiiko Pharmaceutical/Aprogen

Drug Profile

Infliximab biosimilar - Nichiiko Pharmaceutical/Aprogen

Alternative Names: GS 071; NI-071

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Aprogen; Nichiiko Pharmaceutical
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Rheumatoid arthritis

Most Recent Events

  • 08 Dec 2016 Nichiiko Pharmaceutical plans the phase III RADIANCE trial for Rheumatoid arthritis (Adjunctive treatment) in Czech Republic, Poland, Russia, Spain, Ukraine, USA and United Kingdom (IV) (NCT02990806)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2016 Nichiiko Pharmaceutical completes a phase III trial in Rheumatoid arthritis (Adjunctive treatment) in Japan (IV) (NCT01927263)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top